Fast Five Quiz: Genetic/Biomarker Testing in Melanoma

The utility of PD-L1 as a biomarker requires further exploration, but it is theorized that immunohistochemistry testing for PD-L1 may help identify patients who are more likely to respond to immune checkpoint inhibitors. High PD-L1 expression (> 5%) may predict equivalent outcomes with nivolumab monotherapy vs combination ipilimumab and nivolumab therapy in patients with unresectable or metastatic melanoma. Low PD-L1 expression, however, may predict worse outcomes with nivolumab monotherapy vs ipilimumab and nivolumab combination therapy. Ultimately, the use of PD-L1 expression cannot yet be used to guide treatment decisions.

Learn more about the workup for malignant melanoma.

Medscape © 2022 WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: Adil Daud. Fast Five Quiz: Genetic/Biomarker Testing in Melanoma - Medscape - Feb 22, 2022.